Tourmaline Bio, Inc. (NASDAQ:TRML) Director Buys $17,310.00 in Stock

Tourmaline Bio, Inc. (NASDAQ:TRML) Director Parvinder Thiara acquired 1,000 shares of the stock in a transaction dated Friday, November 17th. The shares were bought at an average cost of $17.31 per share, for a total transaction of $17,310.00. Following the acquisition, the director now owns 83,782 shares in the company, valued at approximately $1,450,266.42. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Tourmaline Bio Stock Up 5.8 %

NASDAQ:TRML traded up $0.97 on Monday, hitting $17.65. The company’s stock had a trading volume of 30,207 shares, compared to its average volume of 41,895. Tourmaline Bio, Inc. has a one year low of $8.90 and a one year high of $32.90. The firm has a market capitalization of $75.54 million, a price-to-earnings ratio of -1.18 and a beta of 2.26.

Analysts Set New Price Targets

Several research firms recently commented on TRML. Piper Sandler began coverage on Tourmaline Bio in a research report on Wednesday, October 25th. They set an “overweight” rating and a $65.00 target price for the company. Truist Financial assumed coverage on Tourmaline Bio in a research report on Friday. They issued a “buy” rating and a $43.00 price objective for the company. Finally, Guggenheim assumed coverage on Tourmaline Bio in a research report on Tuesday, October 31st. They set a “buy” rating and a $50.00 target price for the company.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.